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Summary Recent studies have demonstrated a consistent inverse relationship between oestrogen receptor
(ER) and epidermal growth factor receptor (EGFR) levels in female human breast cancer. Serial cross-section
studies have suggested that separate populations of ER + /EGFR - and ER - /EGFR+ cancer cells exist in
tumours deemed by immunocytochemical assay (ICA) to be positive for both. We have developed a dual ICA
that is able to stain for both ER and EGFR on a single 5 jim frozen section sample of breast tissue.
Twenty-two samples of female human breast cancer tissue that exhibited positivity for ER and EGFR by
ER-ICA using the H222 monoclonal antibody and EGFR-ICA using the EGFR1 monoclonal antibody
underwent the dual ICA. There was a significant correlation in receptor positivity between the single and dual
assays for bdth ER (r, = 0.801, P<0.001) and EGFR (rs = 0.831, P<0.001). Individual cancer cells exhibited
one of three staining patterns: nuclear staining only (ER+/EGFR-), membrane-associated and cytoplasmic
staining only (ER-/EGFR+) or no staining (ER-/EGFR-). No cancer cells exhibited both nuclear and
membrane/cytoplasmic staining. This is the first description of a simultaneous dual immunocytochemical assay
system for ER and EGFR in clinical breast cancer specimens. The results suggest that ER and EGFR
expression are mutually exclusive within an individual breast cancer cell in vivo with separate populations of
ER+/EGFR- cells, ER-/EGFR+ cells and ER-/EGFR- cells coexisting.
Oestrogens are essential factors in the growth and develop-
ment of normal breast tissue (Laron et al., 1989) and act via
specific nuclear receptors (ERs) (Gorski et al., 1986). In the
normal breast oestrogens act as mitogens and also induce the
progesterone receptor, which is required for development and
differentiation (Horwitz et al., 1985). However, it has long
been known that oestrogenLs have an important role in the
development and subsequent progression of human breast
cancer (Seibert & Lippman, 1982). More recently evidence
has emerged suggesting that oestrogenic effects are mediated
to some degree by peptide growth factors and their receptors
(Lippman & Dickson, 1989).
These peptide growth factors along with their receptors are
now being increasingly recognised for the role that they play
in the growth and differentiation of both normal (Rowe &
Friesen, 1984) and malignant tissue (Lippman et al., 1988).
Of these, the epidermal growth factor receptor (EGFR) is of
particular interest in human breast cancer. Human EGFR is
a high-affinity transmembrane receptor glycoprotein with a
molecular weight of 170,000 (Cohen et al., 1982). It consists
of an external ligand-binding domain, a transmembrane sec-
tion and a cytoplasmic or internal domain that contains a
tyrosine-specific protein kinase (Downward et al., 1984).
Many studies in recent years have shown an inverse rela-
tionship between ER and EGFR in female human breast
cancer (Sainsbury et al., 1985; Toi et al., 1989; Lewis et al.,
1990). EGFR expression in human breast cancer is associated
with a number of features of poor prognosis, including high
tumour grade (Hainsworth et al., 1991), lymphatic invasion
(Toi et al., 1989, 1990), lymph node involvement (Hains-
worth et al., 1991) and markers of increased cellular pro-
liferation such as Ki-67 (Toi et al., 1990). It has also been
shown to be significantly associated with resistance to hor-
mone therapy (Nicholson et al., 1990), reduced relapse-free
period (Lewis et al., 1990; Nicholson et al., 1990) and
reduced overall survival (Nicholson et al., 1990). There are
some studies that dispute these findings, and these have been
extensively reviewed elsewhere (Klijn et al., 1992).
This inverse relationship with all its implications for prog-
nosis has been the subject of intense study. Initial investiga-
tions involved the use of biochemical ligand-binding assays
and revealed that ER could be detected in 60-80% of
human breast cancers (McGuire et al., 1975) and EGFR in
45% (Klijn et al., 1992). These studies involved the
homogenisation of sample tissue and thus were unable to
address the issues of tumour heterogeneity, such as which
cells were receptor positive (e.g. benign or malignant) or
what proportion of cancer cells were receptor positive. The
development of monoclonal antibodies and immunocyto-
chemical assays specific for ER (King & Greene, 1984) and
EGFR (Waterfield et al., 1982) on frozen sections addressed
these issues. The results of the ER immunocytochemical
assay (ER-ICA) using the monoclonal antibody H222 shows
high concordance with the biochemical ligand-binding assays
(McClelland et al., 1986). ER is immunolocalised in the
nuclei of target cells (King & Green, 1984; King et al., 1985),
and human breast cancer is found to have a heterogeneous
population of ER-positive cells and ER-negative cells (King
et al., 1985). The EGFR immunocytochemical assay (EGFR-
ICA) using the monoclonal antibody EGFR1 (Waterfield et
al., 1982) localises EGFR on the cellular membrane and this
also displays a heterogeneous distribution (Toi et al.,
1989).
Studies have tried to examine the heterogeneous distribu-
tion of ER and EGFR at the individual cellular level by
examining serial cross-sections of frozen breast cancer (Toi et
al., 1989). The results suggested that EGFR was selectively
stained on ER-negative cells and cell groups in tumours
categorised to be positive for both. However, the technique
of taking serial cross-section samples is open to the criticism
that the same cell or cell groups are not being examined in
different sections. To address this issue we have developed a
dual immunocytochemical assay (D-ICA) that is able to stain
for both ER and EGFR on a single 5 jLm frozen section
sample of tumour cell lines (Sharma et al., 1994). This assay
was able to detect all four phenotypes with respect to ER
and EGFR (ER+/EGFR-, ER-/EGFR+, ER-/EGFR-
and ER+/EGFR+). In the present study we have modified
this assay to examine female human breast cancers that have
been categorised to be positive for both receptors by ER-ICA
and EGFR-ICA.
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Materials and methods
Materials
The tissues used for analysis were obtained from 22 patients
who had previously been categorised to be positive for ER
and EGFR by immunocytochemical assay. Of the 22 patients
(age range 35-81 years), nine were premenopausal and 13
were post-menopausal (Table I). All the samples were
obtained from primary breast cancer patients undergoing
mastectomy or wide local excision or from excision of
locoregional recurrences in patients who had not received
any form of adjuvant therapy.
The samples were snap frozen within 30 min of excision in
liquid nitrogen or dry ice. They were then placed in indivi-
dual flexible plastic moulds that contained a semiviscous
freezing compound (OCT, Miles Laboratories, Naperville,
IL, USA), snap frozen to - 70°C in dry ice and stored at
- 70°C. Five micron cryostat sections were cut and thaw
mounted onto poly-L-lysine tissue adhesive-coated glass slides
and immediately either underwent the fixation procedure for
the ER-ICA, EGFR-ICA and D-ICA or were stained with
haematoxylin-eosin for histological examination. All 22
samples were deemed histologically assessable on the
haematoxylin-eosin preparation. Repeat ER-ICA and
EGFR-ICA and the D-ICA were performed on all 22
samples.
ER-ICA
The cryostat sections were fixed in 3.7% formaldehyde-PBS
(0.01 M phosphate-buffered saline) for 15 min, washed twice
for 5 min in PBS, fixed at -10°C in absolute methanol for
6 min followed by immersion in acetone at -10°C for 3 min
then washed again in PBS (2 x 5 min). The sections were
then stored -20°C in a glycerol-sucrose specimen storage
medium for up to 7 days prior to staining. The reagents used
for staining were obtained in kit form (ER-ICA monoclonal,
Abbott Laboratories, North Chicago, IL, USA). After block-
ing non-specific binding with normal goat serum (NGS,
15 min), the staining procedure involved sequential incuba-
tions, with intervening PBS washes (2 x 5 min), with rat
monoclonal anti-ER or control normal rat IgG (30 min),
bridging goat anti-rat IgG (30 min), rat peroxidase-anti-
peroxidase complex (30 min) and diaminobenzidine (DAB)-
hydrogen peroxide-chromogen substrate solution (6 min).
The indirect peroxidase-anti-peroxidase procedures of the
assay are fully described elsewhere (Walker et al., 1988). The
slides were then rinsed in deionised water (2 x 5 min),
counterstained with 1% aqueous methyl green (5 min)
washed again in deionised water (1 min), dehydrated in
graded ethanols (50%, 70%, 90%, 100%), air dried for 1 h,
cleared in xylene and coverslipped using a xylene-soluble
mountant.
Parallel control sections using normal rat IgG antiserum
were run to check for non-specific staining. Inclusion of
control slides of MCF-7 cells enabled inter-assay variations
to be monitored. Brown nuclear staining is observed in ER-
positive cells following the ER-ICA.
EGFR-ICA
The cryostat sections were air dried for 1 h prior to storage
in a sealed box at - 70°C for up to 7 days prior to assay.
The slides were rehydrated in PBS followed by fixation in
50:50 chloroform-acetone at 4°C (10 min) followed by
washing in PBS (2 x 5 min). The sections were then
incubated with 10% normal goat serum (NGS) in PBS to
block non-specific antibody binding. Excess serum was
removed and mouse monoclonal primary anti-EGFR
antibody (EGFR1, Amersham International, UK) or a con-
trol mouse anti-sheep erythrocyte antibody (MASE, sera-
Lab, UK) was added (60min). EGFR1 was added at
1 ig ml-' with 10% NGS and 5% normal human serum
(NHS) in PBS. This monoclonal antibody detects the native
folded external domain of human EGFR and does not com-
pete with EGF for binding with EGFR. The control
antibody was added at a similar concentration to parallel
sections of each specimen. Following the primary incubation
the slides were washed in PBS (3 x Smin) followed by
incubation with rabbit anti-mouse peroxidase-conjugated
antiserum (Dakopatts, UK) at 1:50 dilution in PBS and
containing 10% NGS and 5% NHS (30 min). The slides were
then washed in PBS (3 x 5 min) and immunoreactivity was
revealed by incubation with 3-amino, 9-ethylcarbazole (AEC)
containing hydrogen peroxide obtained in kit form (Immu-
stain, DPC, Oxfordshire, UK) for 10min. The slides were
then washed in tap water (2 x 5 min), counterstained with
1% aqueous methyl green (5 min), washed again in deionised
water (1 min) and immediately coverslipped using
Aquamount (Gurr, Poole, UK).
Inclusion of control slides of an EGFR-positive breast
cancer determined by both radioligand binding and
immunocytochemical assays enabled inter-assay variations to
be monitored. Red membrane-associated and cytoplasmic
staining is observed in EGFR-positive cells following the
EGFR-ICA.
D-ICA
The cryostat sections were fixed and stored for up to 7 days
as previously described (Sharma et al., 1993). The slides then
underwent the sequential steps as per the ER-ICA until the
incubation with the DAB-hydrogen peroxide chromogen
substrate solution, which was applied for 10 min. This
extended incubation period achieved maximal colour produc-
tion and was followed by washing in deionised water (5 min)
then PBS (5 min). The sections were then incubated with
20% NGS and 10% NHS in PBS for 30 min to block
non-specific antibody binding. Following the removal of
excess serum EGFR1 at 2pgml-' with 10% NGS and 5%
NHS in PBS was added to the slides that had received the rat
monoclonal anti-ER antiserum for 60 min. MASE, at a
similar concentration, was added to the slides that had
received the control normal rat IgG for 60 min. The EGFR1
had been preincubated with 2.5 volumes of NHS and the
MASE with two volumes of NHS for 30 min prior to final
dilutions. The sections were then washed in PBS (3 x 5 min)
prior to adding the rabbit anti-mouse peroxidase-conjugated
antiserum at 1:50 dilution in PBS with 10% NGS and 5%
NHS (30 min). This had also been preincubated with 2.5
volumes of NHS for 30 min prior to final dilution. The
remaining steps were as per the EGFR-ICA with the excep-
tion that the incubation with AEC lasted 30min.
Assessment andscoring
The sections were examined, using an Olympus BH2 light
microscope with a dual-viewing attachment, by two observers
(A.S. and R.M.) and scored according to the intensity of
staining and proportion of cells stained. For ER, scores 0-3
were allocated by 0 = no staining; 1 = weak nuclear staining;
2 = moderate nuclear staining; and 3 = strong nuclear stain-
ing. For EGFR, scores 0-3 were allocated by 0 = no stain-
ing; 1 = faint cytoplasmic reactivity; 2, distinct cytoplasmic
or weak membrane reactivity and 3 = strong membrane reac-
tivity. A percentage estimation of cancer cells stained was
made for each category and the final result was obtained by
the summation of all cells that displayed any reactivity
(1 + 2 + 3).
Statistical analysis was performed by using Spearman's
rank correlation.
Results
ER-ICA and EGFR-ICA
In agreement with the previous ER-ICA results, brown
nuclear ER staining was immunolocalised in all 22 cases. The
proportion of ER-ICA-positive cells was highly variable
between patients, with positivity ranging from 10% to 90%1034 A.K. SHARMA et al.
(mean = 49%, Figure 1 and Table I). There was marked
heterogeneity in staining intensity between individual cancer
cells.
Similarly, red membrane-associated and cytoplasmic
EGFR staining was also immunolocalised in all 22 cases.
Positivity ranged from 2% to 70% (mean = 21%, Figure 2
and Table I). Heterogeneity between individual cancer cells
was less apparent than with ER staining. No staining was
observed on the control slides in either assay.
D-ICA
Using the dual ER and EGFR assay, the patterns of
immunostaining were essentially similar to those previously
described using the single-assay procedures. Thus, brown
nuclear ER staining was immunolocalised in all 22 cases and
displayed a similar heterogeneous pattern to that seen follow-
ing the ER-ICA (Figure 3), with positivity ranging from 10%
to 90% (mean 46.5%, Figure 1 and Table I). Red membrane-
associated and cytoplasmic EGFR staining was
immunolocalised in 20/22 (90.9%) cases (Figure 4) with
positivity ranging from 0% (two cases) to 80%
(mean= 19.5%, Figure 2 and Table I). There was a
significant correlation between the single and dual assays in
determining both the ER content (r, = 0.801, P<0.001) and
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Figure 1 ER levels in the single and dual immunocytochemical
assays are significantly correlated (r, = 0.801, P<0.001). The bars
represent mean receptor positivity.
Table I Patient data and results
Age Menopausal ER EGFR Dual assay (%)
Case (years) status (%) (%) ER EGFR
1 35 Pre 50 30 50 20
2 36 Pre 65 30 60 30
3 40 Pre 30 10 30 5
4 43 Pre 50 30 30 20
5 43 Pre 40 10 70 10
6 43 Pre 40 10 30 10
7 45 Pre 60 5 70 5
8 45 Pre 20 5 30 10
9 48 Pre 10 10 20 0
10 52 Post 30 60 20 30
11 58 Post 50 10 50 5
12 59 Post 90 5 90 5
13 59 Post 50 10 50 40
14 61 Post 50 10 50 10
15 61 Post 30 70 20 80
16 62 Post 60 5 60 5
17 63 Post 60 40 40 50
18 65 Post 50 20 50 20
19 67 Post 50 30 50 20
20 72 Post 80 20 80 20
21 74 Post 50 40 50 30
22 81 Post 60 2 60 0
the EGFR content (r,=0.831, P<0.001). There was no
staining on the control slides.
Three staining patterns were seen in our samples in the
D-ICA.
1. Brown nuclear staining with no membrane/cytoplasmic
staining (ER+/EGFR- cells).
2. Red membrane/cytoplasmic staining with no nuclear
staining (ER-/EGFR+ cells).
3. No nuclear or membrane/cytoplasmic staining (ER-/
EGFR- cells).
No cells displaying both nuclear and membrane/cytoplasmic
staining were identified (Figure 5). Summation of the propor-
tion of cells expressing either ER or EGFR never exceeded
100% in either the single or dual assays for any individual
patient (Table I).
In this small select group of double-positive patients we
found no significant inverse linear relationship between ER
and EGFR in either the single assays (Figure 6, r, = -0.163)
or the dual assay (Figure 7, r, = - 0.249). With the exception
of two patients EGFR positivity did not exceed 40%.
Discussion
The present study is the first to describe a dual
immunocytochemical assay that will stain for both ER and
EGFR on single 5 ym frozen section samples of clinical
human breast cancer specimens. The results of staining for
ER and EGFR following the D-ICA are similar to those
achieved in the two single assays of proven prognostic
significance (McClelland et al., 1986; Lewis et al., 1990) with
only small variations in the proportion of tumour cells being
detected as positive. Such relatively minor variations may
result from observer errors, which are inherent in
immunocytochemical procedures (McClelland et al., 1991), or
may be due to tumour heterogeneity, which is well
documented (Walker et al., 1988).
Using the dual assay, three phenotypes have been observed
in our series of 22 ER-positive/EGFR-positive samples;
ER+/EGFR- cells, ER-/EGFR+ cells and ER-/EGFR-
cells. Importantly, no ER+/EGFR+ cells were identified,
despite the proven ability of this assay to detect such cells
when they have been artificially constructed by transfection
procedures (Sharma et al., 1994). These data suggest that ER
and EGFR are mutually exclusive within an individual
cancer cell in vivo, a conclusion that is supported by studies
examining the expression of these receptors in serial cross-
section analysis (Toi et al., 1989). An alternative explanation
is that ER+/EGFR+ cells were not detected because of the
relatively small number of cases examined. However, it is
difficult to accrue large numbers of double-positive tumours
as these represent between only 4% (Bilous et al., 1992) to
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Figure 2 EGFR levels in the single and dual assays are also
significantly correlated (r, = 0.831, P<0.001). Mean receptor
positivity is represented by the bars.
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Figure 3 ER-positive/EGFR-negative cells in the D-ICA dis-
playing brown nuclear staining without any membrane-associated
or cytoplasmic staining (original magnification x 990). Figure 6
assays.
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Figure 4 ER-negative/EGFR-positive cells in the D-ICA dis-
playing red membrane-associated and cytoplasmic staining alone
without any nuclear staining (original magnification x 990).
Figure 5 Photograph demonstrating separate populations of
ER-positive/EGFR-negative cells a, and ER-negative/EGFR-
positive cells b, coexisting within an individual human breast
cancer following the D-ICA. No ER-positive/EGFR-positive cells
were observed in the specimens examined (original magnification
x 990).
37% (Bevilacqua et al., 1990) of primary breast cancers using
immunocytochemical analysis.
Although the exact mechanisms responsible for final ex-
pression of ER or EGFR are not fully understood, investiga-
tions in clinical breast cancer specimens have shown gene
amplification with or without rearrangement to be a rela-
tively rare event (Ro et al., 1988; Watts et al., 1992) and is
thus unlikely to significantly contribute to an altered
phenotype. In contrast to this, in vitro studies on human
breast cancer cell lines, while confirming the inverse relation-
ship between ER and EGFR mRNA and protein expression
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Figure 7 Relationship between ER and EGFR in the D-ICA.
(Lee et al., 1990), have also shown that treatment of ER-
positive cell lines by progestins (Ewing et al., 1989) and
12-O-tetradecanoyl phorbol 13-acetate (Lee et al., 1989) in-
creases EGFR binding and mRNA levels with concomitant
decline in ER binding and mRNA. These data suggest that
final receptor expression may be determined by direct regula-
tion of one receptor gene by the product of the other and/or
reciprocal control by a common regulator that has opposite
effects on these receptors at the transcriptional or post-
transcriptional level. The degree to which these findings can
be applied to the in vivo situation is unclear, although it has
been shown that EGFR mRNA is found more commonly in
ER-negative than in ER-positive breast cancer biopsies
(Travers et al., 1988).
Significantly, it is now well established that oestrogen bind-
ing to ER initiates the transcription of various mRNAs,
including transforming growth factor x (TGF-x), a ligand for
EGFR (Roberts et al., 1983). Since TGF-x/EGFR binding
causes down-regulation of EGFR by means of receptor inter-
nalisation (De Larco & Todaro, 1980), the induction of
TGF-o in ER-positive tumours would tend to suppress
EGFR levels. Certainly, EGFR content is higher in the
ER-negative tumours (Bolufer et al., 1990), and the present
study has shown that in 20/22 cases (90.9%) EGFR expres-
sion was 40% or less in these double-positive tumours.
In addition to the ER+/EGFR- and ER-/EGFR+
phenotypes, the current study has also identified ER-/
EGFR- cells. Such cells were also observed in our in vitro
studies (Sharma et al., 1993) and may be a consequence of
ER being a cell cycle-related product (Bouzubar, 1991).
These cell culture studies have shown that MCF-7 cells in Go
are frequently ER negative and are only induced to express
ER as they progress through the cell cycle (Bouzubar, 1991).
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Thus, although these cells are immunocytochemically ER
negative, they are capable of expressing ER given appropri-
ate growth conditions. Similarly, this phenotype is also found
in normal breast tissue and in overtly ER positive tumours,
where their presence can be associated with endocrine sen-
sitivity (Walker et al., 1988). This has led to the suggestion
that they may represent a resting cell population (Nicholson,
1992).
Although, as yet, no single robust theory has evolved to
fully explain the inverse relationship found between ER and
EGFR, it is evident that the emergence of wholly ER-/
EGFR+ tumours heralds a poor outlook for the breast
cancer patient with poor response to endocrine measures
(Nicholson et al., 1990). In this light, we are currently apply-
ing our D-ICA to samples before, during and at the time of
relapse from endocrine therapy to examine the expression of
ER+/EGFR-, ER-/EGFR+ and ER-/EGFR- pheno-
types. These studies may aid our understanding of the cel-
lular mechanisms leading to hormone independence and
endocrine resistance.
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